New combo attack on advanced prostate cancer
NCT ID NCT04109729
Summary
This early-stage study is testing the safety of combining two drugs, nivolumab and Radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to see if this combination is safe and shows early signs of helping control the cancer. The study will enroll about 39 men to monitor side effects and look for changes in cancer-related markers in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.